Third-Party Testing in Dietary Supplements: Why Companies Shouldn’t Grade Their Own Homework
“Hey Mike, come take a look,” my boss called out.
I walked over to his desk.
“Look at this data.”
We leaned over the stability reports, studied the numbers for a few seconds, looked at each other—and burst out laughing.
“Ha! These guys don’t even know how to fudge data properly.”
The Challenge of Stabilizing EPA/DHA in Prenatal Multivitamins
What we were looking at was an EPA/DHA stability report for a prenatal supplement from a supplier that our sourcing team had identified.
EPA and DHA are omega-3 fatty acids commonly included in prenatal multivitamins because of their important role in supporting fetal brain and eye development during pregnancy. DHA in particular is a major structural component of the brain and retina, which is why many healthcare professionals recommend adequate maternal DHA intake throughout pregnancy.
From a formulation perspective, incorporating EPA and DHA into a prenatal supplement is far more complex than simply adding fish oil to a capsule. Omega-3 fatty acids are highly sensitive to oxidation, meaning they can gradually degrade when exposed to oxygen, heat, light, or moisture. As oxidation occurs, the oil can develop a strong fishy odor, unpleasant aftertaste, reduced potency, and degradation compounds that compromise product quality.
These challenges become even more significant in prenatal formulations because prenatal multivitamins often contain minerals such as iron and copper, which can accelerate oxidation of omega-3 oils. Combining sensitive fatty acids with reactive vitamins and minerals inside the same product requires careful formulation strategy, ingredient selection, manufacturing controls, and packaging design.
In practice, maintaining stability in a prenatal omega-3 formulation requires more than high-quality fish oil alone. Manufacturers must carefully manage oxygen exposure during production, use appropriate antioxidant systems, select compatible ingredient forms, and conduct rigorous stability testing to ensure the product remains potent, stable, and acceptable in taste and smell throughout its shelf life.
At the time, our R&D team had already spent more than a year working to optimize the stability of our prenatal EPA/DHA formulation, particularly in combination with iron-containing multivitamin ingredients, and we still had not completely solved every challenge. To keep our planned launch timeline on track, we asked our sourcing team to identify potential external manufacturing partners with expertise in omega-3 prenatal formulations.
But the report sitting in front of us, if genuine, was nothing short of miraculous.
The formulation's EPA/DHA supposedly remained at 100% of label claim for 24 straight months, with no detectable impurities throughout the entire study.
In this industry, results like that rarely signal perfection. More often, they signal something else entirely.
When “Perfect Data” Is a Red Flag
Unfortunately, this was not the first time we had encountered suspiciously flawless data.
In the Ranbaxy Laboratories data integrity scandal, regulators uncovered widespread data integrity issues involving manipulated test records and questionable quality documentation.1
A similar pattern emerged during inspections involving Wockhardt regulatory compliance investigations, where regulators raised concerns about laboratory practices and the reliability of quality data used to support product approvals and ongoing compliance.2
Cases like these are reminders that data is only as trustworthy as the character and integrity of people behind it.
Over the years, I have learned that most quality failures do not begin with incompetence. They often begin with pressure.
The Quiet Pressure Behind Pharmaceutical Data
In many generic pharmaceutical and dietary supplement companies, technical departments are viewed as necessary cost centers rather than strategic assets. Quality Assurance and Quality Control exist because regulators require them to exist.
Sales and marketing, meanwhile, are often viewed as the hunters of the tribe. The people who “bring home the bacon.” Naturally, they tend to carry more organizational influence.
That imbalance creates pressure.
And under pressure, inconvenient data can suddenly become very unpopular.
I remember one product launch that had already been delayed twice. Marketing brochures had been printed. Sales representatives had completed training. The launch ballroom was booked. Champagne and shrimp cocktails were probably already on the way.
Then the analytical results came back.
Dissolution was slightly outside specification. Nothing catastrophic, but serious enough to raise legitimate concerns.
Operations wanted the batch released immediately for pipeline inventory. Sales argued that another delay would “damage momentum.” Marketing insisted competitors were moving faster.
Suddenly, the technical team became the villain because we were the only people in the building still emotionally attached to quality standards.
I still remember one executive saying:
“Can’t you guys just be more commercially minded?”
That is roughly equivalent to asking an airline mechanic to become more “schedule-oriented” after discovering a crack in an aircraft engine.
Fortunately, my boss calmly closed the meeting folder, pointed at the company logo with the tagline Trusted Quality Healthcare, and said:
“Trust is difficult to build and easy to destroy. We need to get to the bottom of this.”
Luckily, my boss had the full support of the board of directors, which allowed him to push back against pressure from operations.
To this day, it remains one of the best lines I have ever heard in pharma.
“Let’s Just Test Another Sample”
Every QC laboratory eventually experiences this moment.
A batch of dietary supplement fails specification. The room goes quiet. Then someone says:
“Maybe the sample wasn’t representative. Let’s just test another one.”
Over the years, I have heard countless stories from industry veterans about batches that failed assay (potency) testing repeatedly—until, after enough retests, one result barely squeaked within specification.
Suddenly, the room lights up like someone just discovered the cure for cancer.
“See? We knew the product was fine.”
No. Statistically speaking, the batch had simply been interrogated until it finally confessed to a passing result.
Sometimes I joke that certain companies do not perform analytical testing. They perform hostage negotiations with the data.
“Maybe the Specification Is the Problem”
One incident still stands out vividly.
“Hi Rick, what’s going on?”
“Michael, I’ve got bad news. We produced a batch of your Vitamin C and zinc product, but the zinc potency is consistently low.”
Rick represented one of our long-time toll manufacturers, so the call caught me by surprise.
“What happened? Did anything change?”
“No, everything stayed the same. Same manufacturing process. Same testing procedure. But this time we’re only recovering about 85% of zinc.”
Then came the proposed solution.
“Your operations team has been bombarding me with calls. I know you’re running low on stock. Your current zinc release specification is not less than 90%, but regulations only require not less than 80%. If you adjust the specification to 80%, we could release the batch.”
This is one of the most dangerous ideas in quality control:
If the product cannot meet the specification, perhaps the specification itself is the problem.
By that logic, if your bathroom scale says you gained ten kilos, perhaps gravity is simply being too strict.
I discussed the issue with my boss. His response was immediate.
“No. We are not doing that.”
Then he added:
“I think they’re still using the titration assay method. Ask them to send it to a third-party lab that can run Atomic Absorption Spectroscopy. Terrence has the AAS zinc assay procedure.”
So we did.
A few days later, Rick called back sounding noticeably relieved. Using Atomic Absorption Spectroscopy, the independent laboratory recovered 100% of zinc.
Eventually, we identified the root cause. One of the thickening excipients had arrived at the upper end of its viscosity specification and was significantly more viscous than usual. The increased viscosity created interactions between the zinc and the matrix, resulting in incomplete extraction during the original assay procedure.
In the end, the product was fine.
But what stayed with me was how quickly the first instinct had been to lower the specification rather than investigate the root cause.
How many companies, facing inventory shortages and commercial pressure, would have taken the easier path?
Why Third-Party Testing Actually Matters
This is precisely why third-party testing matters.
An independent laboratory has no launch deadline and no warehouse full of inventory waiting to be released. Its only job is to analyze the product and report what the data actually says. They get paid whether the result is positive or negative.
Third-party testing serves as a safeguard against internal pressure and against the very human temptation to “massage” inconvenient results.
It also creates accountability. People behave differently when they know another laboratory may independently verify their work.
For consumers, third-party testing provides an important layer of confidence that what appears on the label more closely reflects what is actually inside the bottle.
The Amazon Effect: Why Supplement Testing Standards Are Rising
This is where I have to give some credit to Amazon.
Beginning in 2020, Amazon significantly tightened its requirements for dietary supplements sold on its platform, particularly around safety, testing, and documentation.
Today, supplement listings increasingly require third-party laboratory testing, Certificates of Analysis, and supporting documentation demonstrating ingredient identity, potency, and the absence of harmful contaminants. In certain high-risk categories, sellers may also need testing for undeclared pharmaceutical ingredients and adulterants.
Operationally, companies are expected to maintain batch-specific documentation and provide Certificates of Analysis for individual production lots when requested.
In other words, it is no longer enough to wave around a beautiful marketing brochure and declare that a product is “premium.” At some point, someone may actually ask to see the paperwork behind the promises.
Is the system perfect? Of course not.
But after spending years in this industry, I can say that forcing companies to produce real testing documentation has meaningfully raised the bar. It has become far more difficult for questionable operators to throw fairy dust into capsules, design a shiny label, and disappear into the internet wilderness.
Frankly, some supplement companies fear third-party testing the same way vampires fear sunlight. The more transparency enters the system, the fewer places there are for bad data, bad practices, and bad products to hide.
Final Thoughts: Quality Is Ultimately a Character Issue
After years in the pharmaceutical and supplement industry, I have learned something simple:
Most quality failures do not begin with malicious intent.
They begin with small compromises.
A retest here.
A delayed investigation there.
A temporary adjustment made to avoid missing a deadline.
Over time, those compromises accumulate until the data no longer reflects reality. It reflects what management wishes reality looked like.
Good quality requires more than sophisticated equipment and polished reports. It requires people who are willing to tell the truth—and stand behind it—even when that truth is inconvenient, expensive, or unpopular.
At the end of the day, the integrity of a product is inseparable from the integrity of the people behind it.
Reference
1. https://www.fda.gov/media/74752/download
2. https://www.fiercepharma.com/manufacturing/fda-bans-a-third-wockhardt-plant
Important Note
This article is intended for educational and informational purposes only. Statements regarding dietary supplements have not been evaluated by the Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease.
